Study of the resistance of Mycobacterium tuberculosis to the principal tuberculostatics (Hospital of Navarra 1996-2003);Estudio de la resistencia de Mycobacterium tuberculosis a los principales tuberculostáticos (Hospital de Navarra 1996-2003)

Anales del Sistema Sanitario de Navarra

Volumn 28, Issue 1, 2005, Pages 29-34

  Dorronsoro, I ^a   Ojer, M ^a   Ruz, A ^a   Navascues A ^a   Gastesi, C ^a   Salicio, Y ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Incidence; Resistances; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; COMORBIDITY; EVALUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; IMMUNE DEFICIENCY; INCIDENCE; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; OSCILLATION; PRACTICE GUIDELINE; PROGNOSIS; RISK FACTOR; SENSITIVITY ANALYSIS; SPAIN; TUBERCULOSIS;

EID: 17144395205     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BARNES PF, BLOCH AB, DAVIDSON PT, SNIDER DE JR. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1644-1650.
2. BRUDNEY K, DOBKIN J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144: 745-749.
3. RAVIGLIONE MC, SNIDER DE JR, KOCHI A. Global epidemiolgy of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
4. FRIEDEN TR, STERLING T, PABLOS-MENDEZ A, KILBURN JO, CAUTHEN GM, DOOLEY SW. The Emergence of Drug-Resistant Tuberculosis in New York City. N Engl J Med 1993; 328: 521-527
5. ABE C, HIRANO K, WADA M, AOYAGI T. Resistance of Mycobacterium tuberculosis to four first-line anti-tuberculosis drugs in Japan, 1997. Int J Tuberc Lung Dis 2001; 5: 46-52.
6. GRANICH RM, BALANDRANO S, SANTAELLA AJ, BINKIN NJ, CASTRO KG, MARQUEZ-FIOL A et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997. Arch Intern Med 2000; 160: 639-644.
7. ARAJ GF, ITANI LY, KANJ NA, JAMALEDDINE GW. Comparative study of antituberculous drug resistance among Mycobacterium tuberculosis isolates recovered at the American University of Beirut Medical Center. 1996-1998 VS 1994-1995 J Med Liban 2000; 48: 18-22.
8. TORRES L, ARAZO P, PÉREZ JB, AMADOR MP, LEZCANO MA, REVILLO MJ, GARCÍA-MOYA JB. Resistencia de Mycobacterium tuberculosis en Zaragoza (1993-1997) y factores asociados. Med Clin (Barc) 2000; 115: 605-609.
9. Grupo de estudio de Tuberculosis Resistente en Madrid. Estudio transversal multihospitalario de tuberculosis y resistencias en Madrid (octubre de 1993-abril de 1994). Med Clin (Barc) 1996; 106: 1-6.
10. FLAMENT-SAILLOUR M, ROBERT J, JARLIER V, GROSSET J. Outcome of multi-drug-resistant tuberculosis in trance: a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593.
11. LUNDH K. Swedres 2003: report on Swedish antibiotic utilisation and resistance in human medicine. Swedish Institute for Infectious Disease Control, Solna, Sweden Eurosurveillance Weekly 2004; 8y: 01/07/2004
12. CALLISTER MEJ, BARRINGER J, THANABALASINGAM ST, GAIR R, DAVIDSON RN, Pulmonary tuberculosis among political asylum seekers screened at Heathrow Airport, London, 1995-9. Thorax 2002; 57: 152-156.
13. KENT PT, GP KUBICA. Public Health Mycobacteriolgy: a Guide for the Level III Laboratory. U.S. Department of Health and Human Services, Centers for Disease Control. Division of Laboratory training and Consultation. Atlanta GA 1985.
14. SIDDIQI SH. BACTEC 460TB SYSTEM Product and Procedure Manual. MA-0029 Becton Dickinson and Company 1995.
15. PERFECTO B, SANCHIZ JR, GONZÁLEZ AI, LÓPEZ I, DORRONSORO I. Brote de tuberculosis multirresistente. An Sist Sanit Navar 2000; 23: 257-263.
16. CASAL M, GUTIÉRREZ J, RUIZ P. Estado actual de la resistencia múltiple a fármacos en la tuberculosis. Rev Esp Quimioter 2000; 13: 167-170.
17. MARTIN-CASABONA N, ALCAIDE F, COLL P, GONZÁLEZ J, MANTEROLA JM, SALVADO M et al. Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Med Clin (Barc) 2000; 115: 493-498.
18. BAILEY WC, BASS JB, HAWKINS JE et al. Drug susceptibility testing for mycobacteria. Am Thorac Soc Newsl 1984; 10: 9-10.
19. KUBICA GP, DYE WE. Laboratory Methods for Clinical and Public helth Mycobacteriology. U.S. Government Printing Office. Washington D.C. 1967.
20. TENOVER FC, CRAWFORD JT, HUEBNER RE, GEFTER LJ, HORSBURGH CR JR, GOOD RC. The resurgence of Tuberculosis: Is your laboratory ready? J Clin Microbiol 1993; 31: 767-770.
21. DOERN GV. Diagnostic mycobacteriology: were are we today? J Clin Microbiol 1996; 31: 767-770.
22. Grupo de trabajo del PMIT. La tuberculosis en Espana: resultados del Proyecto Multicéntrico de Investigación sobre Tuberculosis (PMIT). Ed. Instituto de Salud CarlosIII, Madrid 1999; 94.
23. CARNICER-PONT D, RUSSELL R, WALAPU M, MORGAN S, WILLIAMS A, LLEWELLYN-JONES C et al. Tuberculosis in portuguese migrant workers in Wales, June 2004. Eurosurveillance Weekly 2004; 8: 01/07/2004.
24. BECERRA MC, FREEMAN J, BAYONA J, SHIN SS, KIM JY, FURIN JJ et al. Using treatment failure under effective directly observed short course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114.
25. BECERRA MC, BAYONA J, FREEMAN J, FARMER PE, KIM JY. Redefining MDR-TB transmision "hot spots". Int J Tuberc Lung Dis 2000; 4: 387-394.
26. MITNICH C, BAYONA J, PALACIOS E, SHIN S, FURIN J, ALCÁNTARA F et al. Comunity-Based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.